Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063906
Chunk: 225

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 225
---
 of their clinical drug candidates that may have been shelved for pure business reasons unrelated to safety or efficacy, even though they have met their endpoints and have proven themselves to be safe. If such drugs were to be repositioned, the pharmaceutical company increases the attractiveness of these drugs and gives itself more options to find interested buyers. ( https: // www. ddw -online .com / the -benefits - of-drug -repositioning-1779-201104 /) •Lower failure rate: According to BCC Research, approval rates for repurposed drugs are close to 30%, which is greater than the approval rate for new drug applications. (Front Oncol. 2017; 7: 273) One of the major limitations of the current drug repurposing and repositioning practice is that there is a lack of a systematic way to identify and reinvestigate drugs that are approved and/or have failed approval. SACT -1is the first repurposed drug candidate to be developed under the Smart -ACT ®drug discovery platform. SCAT -1is one of the Company’s proprietary technologies. Our first targeted indication is neuroblastoma. Neuroblastoma is a rare form of cancer, and classified as an orphan disease, that forms in certain types of nerve tissue and most frequently in the adrenal glands as well as spine, chest, abdomen or neck, predominantly in children, especially for those aged 5 years and below. For the high -riskgroup, which is close to 20% (Annu Rev Med. 2015; 66: 49 – 63.) of total new patient population per year, the 121 5 -yearsurvival rate of this condition is around 40 -50% as observed by the American Cancer Society ( https://www.cancer.org/cancer/neuroblastoma/detection -diagnosis-staging / survival -rates .html). The current high drug treatment cost for high -riskpatients can average USD200,000 per regimen (all 6 cycles) ( https://www.cadth.ca/ sites/default/files/pcodr/Reviews2019/10154DinutuximabNeuroblastoma_fnEGR_NOREDACT -ABBREV_Post_26Mar2019_final .pdf). In addition, most pediatric patients often do not tolerate or survive the relevant chemotherapy stage which, subject to further clinical studies, may be positively addressed by the SACT -1candidate due to the potential synergistic effects